Role of enoxaparin resistance in recurrent chest pain in the intensive care unit.

about

Role of enoxaparin resistance in recurrent chest pain in the intensive care unit.

Item

http://www.wikidata.org/entity/Q43237435

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Role of enoxaparin resistance in recurrent chest pain in the intensive care unit.

@en

Role of enoxaparin resistance in recurrent chest pain in the intensive care unit.

@nl

type

Item

label

Role of enoxaparin resistance in recurrent chest pain in the intensive care unit.

@en

Role of enoxaparin resistance in recurrent chest pain in the intensive care unit.

@nl

prefLabel

Role of enoxaparin resistance in recurrent chest pain in the intensive care unit.

@en

Role of enoxaparin resistance in recurrent chest pain in the intensive care unit.

@nl

P1476

Role of enoxaparin resistance in recurrent chest pain in the intensive care unit.

@en

P2093

A A Ozkan

http://www.w3.org/2001/XMLSchema#string

A Hatemi

http://www.w3.org/2001/XMLSchema#string

Aysem Kaya

http://www.w3.org/2001/XMLSchema#string

B Okcun

http://www.w3.org/2001/XMLSchema#string

H E Ataoglu

http://www.w3.org/2001/XMLSchema#string

I Uzunhasan

http://www.w3.org/2001/XMLSchema#string

M Baskurt

http://www.w3.org/2001/XMLSchema#string

N Turhan

http://www.w3.org/2001/XMLSchema#string

Z Yigit

http://www.w3.org/2001/XMLSchema#string

P2860

Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide

Factor Xa inactivation in acute coronary syndrome.

Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: a combined analysis.

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial.

Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.

Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study).

Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.

Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study.

Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes.

P304

1436-1442

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/147323000903700518

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2009-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40024278

http://www.w3.org/2001/XMLSchema#string

P698

19930848

http://www.w3.org/2001/XMLSchema#string

P921

intensive care unit